pre-IPO PHARMA

COMPANY OVERVIEW

Slayback Pharma LLC is a specialty pharmaceutical company focused on developing, manufacturing and sourcing of complex generic pharmaceutical products, with a specific emphasis on complex injectables and other non-solid oral products. Slayback has created a unique portfolio of complex generics by smart product selection and execution and connecting various dots through a network of contract R&D laboratories and manufacturing organizations, comprising smart and rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies.


LOCATION

  • Princeton, NJ, USA

  • THERAPEUTIC AREAS

  • Women's Health

  • WEBSITE

    http://www.slayback-pharma.com


    CAREER WEBSITE

    http://www.slayback-pharma.com/careers/


    SOCIAL MEDIA


    INVESTORS

    kkr


    PRESS RELEASES


    Feb 4, 2021

    Slayback Pharma announces launch of Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg, generic equivalent of Taytulla


    Dec 18, 2020

    Slayback Pharma announces FDA approval of Merzee, generic equivalent of Taytulla with a Competitive Generic Therapy (CGT) Designation


    Dec 7, 2020

    Slayback Pharma Appoints Dr Sumitra Pillai as Head of RandD


    Sep 2, 2020

    Slayback Pharma announces approval of Icatibant Injection 30 mg/3 ml (10 mg/ ml), generic equivalent of Firazyr.


    Aug 17, 2020

    Slayback Pharma Appoints Lori A. Hoffman as Head of Alliance Management


    For More Press Releases


    Google Analytics Alternative